Table 1 Baseline characteristics of the COVID-19 ICU-cohort
| Â | RRT-cohort | Non-RRT-cohort |
|---|---|---|
n = 23 | n = 48 | |
Age | ||
 Median (range), y | 62 (38–79) | 70 (44–92) |
  ≥ 65 y | 9 (39) | 30 (63) |
Female | 4 (17) | 13 (27) |
Admission diagnosis COVID-19 | 18 (78) | 37 (77) |
Non-renal comorbiditiesa | ||
 Any | 20 (95) | 38 (79) |
 Asthma/COPD | 2 (10) | 3 (6) |
 Atrial Fibrillation | 3 (14) | 12 (25) |
 Coronary Artery Disease | 3 (14) | 10 (21) |
 Hypertension | 12 (57) | 19 (40) |
 Malignancy | 4 (19) | 7 (15) |
 Diabetes mellitus | 4 (19) | 10 (21) |
 Obesity | 3 (14) | 3 (6) |
Renal | ||
 CKD ≥ G2b | 2 (12) | 7 (15) |
 Acute Kidney injury ≥ Stage 1 | 23 (100) | 30 (63) |
 Creatinine, baselineb, mg/dL | 1.00 (0.80–1.14) | 0.90 (0.70–1.10) |
 Creatinine max, mg/dL | 5.99 (3.32–7.93) | 1.52 (1.04–2.98) |
 SARS-CoV-2-PCR to RRT-initiation, d | 9 (0–39) |  |
Mechanical cardiorespiratory support | ||
 Invasive mechanical ventilation | 22 (96) | 30 (63) |
 Vasopressor administration | 23 (100) | 34 (71) |
 Extracorporeal membrane oxygenation | 10 (43) | 11 (23) |
Inflammation markers, max. | ||
 C-reactive protein, mg/L (NR: < 5)c | 311 (223–394) | 240 (170–331) |
 Procalcitonin, μg/L (NR: < 0.05) | 18.80 (8.70–43.80) | 0.99 (0.38–3.49) |
 Interleukin 6, ng/L (NR: < 7)d | 1889 (710–14,403) | 320 (112–848) |
 Ferritin, μg/L (NR: 30–400)e | 2565 (1493–3880) | 1612 (807–2719) |
COVID-19 targeted therapy | ||
 any | 20 (87) | 40 (83) |
 Hydroxychloroquine | 19 (83) | 36 (75) |
 Lopinavir, Ritonavir | 13 (57) | 22 (46) |
 Remdesivir | 0 (0) | 1 (2) |
 Tocilizumab (Anti-IL6) | 3 (13) | 3 (6) |
 Cytokine filter (Cytosorb®) | 1 (4) | 1 (2) |
Death | 12 (52) | 22 (46) |